http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
-
Pfizer (PFE), BioNTech (BNTX) Confirm Phase 3 Study of COVID-19 Vaccine Candidate Shows 95% Efficacy
-
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
-
Exclusive: EU eyes COVID vaccine deal with Moderna at less than $25 per dose, says source
-
Pfizer (PFE) Completes Transaction to Combine Its Upjohn Business with Mylan (MYL)
-
Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan
-
Michigan, Washington state impose severe COVID-19 restrictions as U.S. infections soar
-
Trump briefly admits election defeat, clings to flailing legal strategy
-
Trump appears to acknowledge for first time that Biden could succeed him
-
Fed officials differ over economy's risks as coronavirus surges
-
Pfizer (PFE) Analysis from Phase 3 ATTR-ACT, Extension Study Demonstrates VYNDAQEL 80 mg/VYNDAMAX 61 mg Significantly Improved Survival in Patients with ATTR-CM Compared to VYNDAQEL 20 mg
-
Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (A
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer (PFE) Reports Positive Results from Fifth Phase 3 Trial of Abrocitinib
-
Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimens
-
Pfizer (PFE) and BioNTech (BNTX) Confirm Agreement to Supply EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2
-
Pfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19
-
Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2
-
Transgene Presents E-Poster Outlining Detailed Results from the Phase 1b/2 Trial of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers at SITC 2020
-
Retail trading hits snags as vaccine news sparks stock scramble
-
Pfizer (PFE), BioNTech (BNTX) COVID-19 Vaccine Shows Over 90% Efficacy in Phase 3 Study
-
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
-
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
-
Pfizer (PFE) Announces Positive Phase 3 Study Results for XELJANZ in Ankylosing Spondylitis
-
Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS)
-
Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock
-
Ionis Pharmaceuticals (IONS) Reports Pfizer (PFE) to Begin Phase 2b Clinical Study of Vupanorsen (AKCEA-ANGPTL3-LRx)
-
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
-
Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn
-
Mylan (MYL), Pfizer (PFE) Gain FTC Clearance of Proposed Combination of Mylan and Upjohn
-
Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn
-
Pfizer (PFE) Announces FDA Grants Priority Review and EMA Accepts Regulatory Submission for Abrocitinib for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
-
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
-
Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers
-
Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020
-
Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers
-
GBG and Pfizer (PFE) Announce PENELOPE-B Trial of IBRANCE in Early Breast Cancer Did Not Meet Primary Endpoint
-
PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint
-
Pfizer (PFE) Phase 3 Once-Weekly Investigational Study of Somatrogon to Treat Children with GHD Met its Primary Endpoint
-
Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
-
Pfizer (PFE), Sangamo Therapeutics Inc. (SGMO) Report First Participant Dosing in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
-
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
-
Exact Sciences (EXAS), Pfizer (PFE) Extend and Amend Cologuard Promotion Agreement
-
Exact Sciences and Pfizer Extend and Amend Cologuard® Promotion Agreement
-
U.S. FDA safety guidelines likely to push COVID-19 vaccine authorization past election
-
BioNTech (BNTX) and Pfizer (PFE) Initiate Rolling Submission to EMA for SARS-CoV-2 Vaccine Candidate BNT162b2
-
BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2
-
SpringWorks Therapeutics Inc. (SWTX), Pfizer Inc. (PFE) Report Clinical Collaboration to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myelom
-
SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma
-
SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma

